Wellell Inc

Wellell Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.1, indicating minimal leverage and a strong equity base. The company's liquidity position is characterized as medium, with a current ratio of 3.13, suggesting it can cover short-term obligations but with limited excess cash. Free cash flow of TWD 66.25 million and operating cash flow of TWD 207.45 million support operational flexibility, though cash and equivalents of TWD 89.94 million are modest relative to total assets. Profitability metrics show a return on equity of 4.79% and a return on assets of 3.81%, both below the industry median for medical equipment firms, which typically exceed 6% ROE and 4.5% ROA. Gross profit of TWD 1.1 billion represents 45.9% of revenue, but operating income of TWD 150.83 million reflects a 6.3% margin, which is in line with the industry average. The company's revenue is concentrated in three key regions: Europe, the Americas, and Asia, with no disclosed segment breakdown by geography. This lack of geographic diversification introduces concentration risk, particularly in markets with regulatory or economic volatility. The product portfolio is similarly concentrated in wound management, respiratory therapy, and electronic medical devices, with no material diversification into adjacent healthcare services or pharmaceuticals. Outlook for FY2024 shows a projected revenue increase of 4.2% year-over-year, driven by expansion in the Americas and new product launches in the EMD series. Capital expenditure of TWD -52.77 million indicates a reduction in investment, which may signal a shift toward cost optimization rather than growth. The company's net income of TWD 121.12 million in FY2023 reflects a 3.8% margin, which is below the industry median of 5.2%. Risk factors include liquidity constraints, as net cash is negative after subtracting total debt, and a low dilution risk due to no near-term share issuance plans. The company has not disclosed any material regulatory or geopolitical risks, though its exposure to global healthcare markets may be affected by policy shifts in key regions. Recent filings and transcripts do not indicate any material operational or strategic changes in the past six months.